Literature DB >> 25519294

Carbohydrate-to-Insulin Ratio in a Mediterranean Population of Type 1 Diabetic Patients on Continuous Subcutaneous Insulin Infusion Therapy.

Valeria Alcántara-Aragón1, Cintia Gonzalez2, Rosa Corcoy2, Justa Ubeda3, Ana Chico2.   

Abstract

BACKGROUND: The carbohydrate-to-insulin ratio (CIR) is initially calculated from the total daily insulin dose (TDID). However, CIR likely presents variations owing to different population characteristics and intraday variations not being taken into account by most formulas. No information is available concerning the Mediterranean population. We investigated the CIR used by patients with type 1 diabetes (T1DM) using continuous subcutaneous insulin infusion (CSII) therapy in a Mediterranean area, to identify possible intraday variations and establish an adequate formula to calculate CIR.
METHODS: Data from 170 T1DM patients from Barcelona were obtained retrospectively from the Spanish National Registry of CSII Therapy (SNR-CSII). Theoretical CIR was calculated using the formula: 500 divided by TDID. This theoretical CIR was compared to the real CIR.
RESULTS: The real CIR was also compared between main meals. Patients with HbA1c < 7% (n = 44) were considered a reference group for accurate bolus calculation and were analyzed as a subgroup. The real CIR used was 11.5 g/UI for breakfast, 12 g/UI for lunch, and 13.3 g/UI for dinner. CIR obtained by the 500/TDID formula for all meals was 15.5 g/UI. We obtained similar results for the group with HbA1c < 7%. The real CIR differed significantly from the theoretical CIR values and between breakfast and the other main meals (P < .005).
CONCLUSIONS: CIR in our population was significantly lower for breakfast than for other meals. CIR using the 500/TDID formula underestimated prandial insulin requirements. A calculation of 350/TDID for breakfast and 400/TDID for lunch and dinner would be more appropriate for this population.
© 2014 Diabetes Technology Society.

Entities:  

Keywords:  bolus calculator; carbohydrate counting; continuous subcutaneous insulin infusion therapy; insulin-to-carbohydrate ratio; type 1 diabetes

Mesh:

Substances:

Year:  2014        PMID: 25519294      PMCID: PMC4604542          DOI: 10.1177/1932296814563571

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  18 in total

1.  Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels.

Authors:  John Walsh; Ruth Roberts; Timothy Bailey
Journal:  J Diabetes Sci Technol       Date:  2010-09-01

Review 2.  Continuous glucose monitoring-guided insulin dosing in pump-treated patients with type 1 diabetes: a clinical guide.

Authors:  Allen B King
Journal:  J Diabetes Sci Technol       Date:  2012-01-01

3.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

4.  Long-term biomedical and psychosocial outcomes following DAFNE (Dose Adjustment For Normal Eating) structured education to promote intensive insulin therapy in adults with sub-optimally controlled Type 1 diabetes.

Authors:  J Speight; S A Amiel; C Bradley; S Heller; L Oliver; S Roberts; H Rogers; C Taylor; G Thompson
Journal:  Diabetes Res Clin Pract       Date:  2010-04-18       Impact factor: 5.602

5.  Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes.

Authors:  A S Brazeau; H Mircescu; K Desjardins; C Leroux; I Strychar; J M Ekoé; R Rabasa-Lhoret
Journal:  Diabetes Res Clin Pract       Date:  2012-11-10       Impact factor: 5.602

6.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Carbohydrate-to-insulin ratio is estimated from 300-400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump.

Authors:  Akio Kuroda; Tetsuyuki Yasuda; Mitsuyoshi Takahara; Fumie Sakamoto; Ryuichi Kasami; Kazuyuki Miyashita; Sumiko Yoshida; Eri Kondo; Ken-ichi Aihara; Itsuro Endo; Taka-aki Matsuoka; Hideaki Kaneto; Toshio Matsumoto; Iichiro Shimomura; Munehide Matsuhisa
Journal:  Diabetes Technol Ther       Date:  2012-11       Impact factor: 6.118

8.  ProAct study: new features of insulin pumps improve diabetes management and glycemic control in patients after transition of continuous subcutaneous insulin infusion systems.

Authors:  Ralph Ziegler; Claudio Tubili; Ana Chico; Bruno Guerci; Elena Lundberg; Marcus Borchert; Andrea Löffler; Sandra Bloethner; Jörg Weissmann; Andreas Pfützner
Journal:  Diabetes Technol Ther       Date:  2013-08-09       Impact factor: 6.118

9.  Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial.

Authors:  Ralph Ziegler; David A Cavan; Iain Cranston; Katharine Barnard; Jacqueline Ryder; Claudia Vogel; Christopher G Parkin; Walter Koehler; Iris Vesper; Bettina Petersen; Matthias A Schweitzer; Robin S Wagner
Journal:  Diabetes Care       Date:  2013-07-30       Impact factor: 19.112

10.  Hemoglobin A1c Levels and risk of severe hypoglycemia in children and young adults with type 1 diabetes from Germany and Austria: a trend analysis in a cohort of 37,539 patients between 1995 and 2012.

Authors:  Beate Karges; Joachim Rosenbauer; Thomas Kapellen; Verena M Wagner; Edith Schober; Wolfram Karges; Reinhard W Holl
Journal:  PLoS Med       Date:  2014-10-07       Impact factor: 11.069

View more
  2 in total

1.  A Randomized Controlled Study of an Insulin Dosing Application That Uses Recognition and Meal Bolus Estimations.

Authors:  Ewa Pańkowska; Piotr Ładyżyński; Piotr Foltyński; Karolina Mazurczak
Journal:  J Diabetes Sci Technol       Date:  2016-12-20

Review 2.  Boluses in Insulin Therapy.

Authors:  Ralph Ziegler; Guido Freckmann; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2016-07-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.